Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In the phase 3 IMbassador250 clinical trial, a checkpoint immunotherapy combination with enzalutamide did not improve survival over enzalutamide alone in patients with metastatic castration-resistant prostate cancer whose disease progressed on abiraterone. The study uncovered genomic and immune biomarkers that may identify patients deriving benefit.
People with HIV who delay initiation of anti-retroviral therapy have permanent loss of memory T cells in the skin, which may explain their increased risk of skin cancer.
Parents give consent for their children’s health data to be used in research, but what happens when the children reach adulthood, and how can researchers keep families involved in the meantime?
Hypermutation and microsatellite burden determine responses and long-term survival following PD-1 blockade in children and young adults with refractory cancers resulting from germline DNA replication repair deficiency.
A gene therapy phase 1 trial in patients with β-thalassemia shows transplantation of autologous CD34+ cells transduced with a lentiviral globin vector after reduced-intensity conditioning achieves long-term engraftment, albeit not transfusion independence, with benign clonal expansions, warranting cautious monitoring of patients.